Ted Slafsky, publisher and CEO of 340B Report, examines the CBO's recent report on the 340B drug discount program.

Column: A Deep Dive into CBO’s New 340B Report and Why It Significantly Misses the Mark

September 30, 2025 Ted Slafsky, Publisher & CEO 340B Report Views

The respected, nonpartisan Congressional Budget Office (CBO) doesn’t often study the 340B drug discount program; therefore stakeholders need to take [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

Column: A Deep Dive into CBO’s New 340B Report and Why It Significantly Misses the Mark

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Ted Slafsky

Column: A Deep Dive into CBO’s New 340B Report and Why It Significantly Misses the Mark

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Ted Slafsky

Staff Email

Site Footer Live